EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study

Benedetta Pessina iD, Camilla Sertori iD, Simona Barni iD, Francesco Catamerò iD, Giulia Liccioli iD, Erika Paladini, Lucrezia Sarti iD, Leonardo Tomei iD, Julia Upton iD, Claudia Valleriani iD, Francesca Mori iD, Mattia Giovannini iD

Nutrients · 2026

DOI: 10.3390/nu18081252 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Nutrients, 2026. Verfasst von Benedetta Pessina und 11 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Arachis, Allergens. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Peanut oral immunotherapy (P-OIT) is an emerging treatment strategy for peanut allergy (PA). Although a standardized pharmaceutical product, Peanut (Arachis hypogaea) Allergen Powder-dnfp, has been approved in several countries, it is not universally available. In such contexts, real-world protocols using readily utilizable peanut products may represent an alternative approach. This study aimed to describe the feasibility, safety, and clinical outcomes of P-OIT using toasted peanuts in a real-world effort in a pediatric population.

Methods

This single-center retrospective cohort study enrolled children who initiated P-OIT at our tertiary pediatric hospital Allergy Unit between April 2015 and December 2024. Demographic and clinical features, allergy test results, and information about P-OIT were recorded. Desensitization was defined as tolerance of 630 mg of peanut protein (PP).

Results

Sixty patients (51.7% male; median age 8.2 years) were included. 22/60 (36.7%) achieved desensitization within a median time of 22.7 months. 21/60 (35%) were still undergoing P-OIT at a median tolerated dose of 100 mg of PP, and 17/60 (28.3%) discontinued treatment, most commonly due to loss to follow-up (44%). At least one adverse reaction occurred in 43/60 (71.7%) patients, predominantly mild and self-limiting (68.3% resolved spontaneously, 39.5% occurred at home). However, 11/60 (18.3%) showed anaphylaxis, and 3/60 (5%) received adrenaline. A reduction in Ara h 2 serum-specific IgE levels compared to the baseline was observed in patients completing escalation (p = 0.03).

Conclusions

In this real-world single-center cohort, P-OIT using toasted peanuts was feasible in a subset of patients and was associated predominantly with mild adverse reactions, although systemic reactions were also recorded. Treatment discontinuation and adherence remain relevant challenges. These findings highlight the need for prospective, controlled studies to better define the role, safety profile, and patient selection criteria for food-based P-OIT protocols in settings where standardized products are not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peanut HypersensitivityDesensitization, ImmunologicArachisAllergensHumansRetrospective StudiesFemaleMaleChildItalyAdministration, OralChild, PreschoolTreatment OutcomeAdolescentImmunoglobulin E

Stichwörter der Autor:innen

IgEanaphylaxischildrenfood allergyoral immunotherapypeanut

Substanzen

AllergensImmunoglobulin E

Autor:innen und Institutionen

  • Allergy Unit, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.
  • Department of Health Sciences, University of Florence, 50139 Florence, Italy.
  • Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, 53100 Siena, Italy.
  • Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • Immunology Laboratory, Meyer Children's Hospital IRCCS, 50139 Florence, Italy.

ORCID-Profile: Benedetta Pessina, Camilla Sertori, Simona Barni, Francesco Catamerò, Giulia Liccioli, Lucrezia Sarti, Leonardo Tomei, Julia Upton, Claudia Valleriani, Francesca Mori, Mattia Giovannini

Zitieren

APA

Pessina, B., Sertori, C., Barni, S., Catamerò, F., Liccioli, G., Paladini, E., Sarti, L., Tomei, L., Upton, J., Valleriani, C., Mori, F., & Giovannini, M. (2026). Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study. Nutrients. https://doi.org/10.3390/nu18081252

Vancouver

Pessina B, Sertori C, Barni S, Catamerò F, Liccioli G, Paladini E, et al. Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study. Nutrients. 2026. doi:10.3390/nu18081252

BibTeX
@article{Pessina2026,
  author = {Pessina, Benedetta and Sertori, Camilla and Barni, Simona and Catamerò, Francesco and Liccioli, Giulia and Paladini, Erika and Sarti, Lucrezia and Tomei, Leonardo and Upton, Julia and Valleriani, Claudia and Mori, Francesca and Giovannini, Mattia},
  title = {Peanut Oral Immunotherapy in Children: An Italian Single-Center Retrospective Cohort Study},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18081252}
}
Kostenlos starten →